A Dark Vector Cognition product

Item 16. Form 10-K Summary

5K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

Not applicable.

Table of Content

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MODERNA, INC.
Date:By:/s/ Stéphane Bancel
February 24, 2023
Stéphane Bancel
Chief Executive Officer and Director

Table of Content

POWER OF ATTORNEY AND SIGNATURES

Each individual whose signature appears below hereby constitutes and appoints each of Stéphane Bancel and James M. Mock as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Stéphane BancelChief Executive Officer and Director (Principal Executive Officer)February 24, 2023
Stéphane Bancel
/s/ James M. MockChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)February 24, 2023
James M. Mock
/s/ Noubar B. Afeyan, Ph.D.Chairman and DirectorFebruary 24, 2023
Noubar B. Afeyan, Ph.D.
/s/ Stephen BerensonDirectorFebruary 24, 2023
Stephen Berenson
/s/ Sandra Horning, M.D.DirectorFebruary 24, 2023
Sandra Horning M.D.
/s/ Robert Langer, Sc.D.DirectorFebruary 24, 2023
Robert Langer, Sc.D.
/s/ Francois Nader, M.D.DirectorFebruary 24, 2023
Francois Nader M.D.
/s/ Elizabeth Nabel, M.D.DirectorFebruary 24, 2023
Elizabeth Nabel, M.D.
/s/ Paul SaganDirectorFebruary 24, 2023
Paul Sagan
/s/ Elizabeth TallettDirectorFebruary 24, 2023
Elizabeth Tallett

Previous: Item 15. Exhibits, Financial Statement Schedules